Explore Potential Plasma and BALF Immunometabolic and Lipidomic Biomarkers for Identifying ARDS Endotypes

Chinese Academy of Medical Sciences & Peking Union Medical College

Status: Enrolling

Conditions: Acute Respiratory Distress Syndrome; Acute Respiratory Failure

Treatments: Diagnostic Test: Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling

Study type: Observational

Funder types: Other

Identifiers

NCT05451342

ZS-3391

Details and patient eligibility

About

Acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes high mortality (41% to 58%). Previous studies have reported that biomarkers can facilitate phenotypic diagnosis of ARDS, enabling precision treatment of ARDS. Although there were many studies that found some potential therapeutic targets for ARDS, no pharmacotherapies have been validated to treat ARDS. The development of biomarkers to predict the prognosis and monitor the response to treatment would be of interest for selecting patients for specific therapeutic trials. Many recent studies have shown that immune metabolic changes are involved in the pathogenesis of ARDS and may become a new therapeutic target for them. We aimed to identify a panel of immunometabolic and lipidomic biomarkers derived from blood and bronchoalveolar lavage fluid (BALF) which may help differentiate the ARDS endotypes.

Full description

PROTOCOL OUTLINE:

This is an observational study. The blood and BALF samples will be collected from patients with ARDS for exosome extraction and transcriptome and metabolomic analysis.

Exosome characterization and differential genes and metabolites will be identified.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Aged >18 years old;
2. Meet the diagnostic criteria of ARDS according to the Berlin Criteria.

Exclusion criteria

1. Aged≤18 years old;
2. Pregnancy;
3. No informed consent;

Trial design

200 participants in 2 patient groups

ARDS

Description:

Patients who meet the diagnostic criteria of ARDS

Treatment:

Diagnostic Test: Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling

Non-ARDS

Description:

Patients without ARDS

Treatment:

Diagnostic Test: Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling